Symplmed announced the launch of Prestalia (perindopril arginine, amlodipine) tablets for the treatment of hypertension in patients whose blood pressure is not adequately controlled on monotherapy, and as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.
Prestalia is the first fixed-dose combination of perindopril arginine, an angiotensin converting enzyme (ACE) inhibitor, and amlodipine, a dihydropyridine calcium channel blocker (CCB). It is contraindicated in patients with hereditary or idiopathic angioedema, with or without previous ACE inhibitor treatment, and in patients who are hypersensitive to perindopril, to ACE inhibitors, or to amlodipine.
Prestalia tablets are available in 3.5mg/2.5mg, 7mg/5mg, and 14mg/10mg strengths in 90-count bottles through bpCareConnect, Symplmed’s hypertension management program.
For more information call (888) 552-9769 or visit Prestalia-US.com.